Anemia Drugs Given Stronger Warnings

Jamie Sheller
Attorney
(866) 735-1102 Ext 475
Posted by Jamie ShellerMarch 26, 2008 9:59 AM

The makers of Aranesp, Epogen and Procrit have recently been advised by the FDA to expand its black box warnings. The new warnings indicate the risks of death and tumor growth when used by cancer patients with early stage breast cancer or cancer in the head and neck. Aransep, Epogen and Procrit are popular drugs used to treat the blood disorder anemia in patients with kidney failure and those on chemotherapy. http://www.fda.gov/cder/drug/advisory/RHE2007.htm If you, or a family member has been injured by this drug, contact Sheller PC to get more information about your legal rights. We have a team of experienced attorneys who are willing to assist you in every aspect of your case.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Philadelphia

InjuryBoard Philadelphia RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Injury Board Philadelphia is brought to you by Sheller, P.C.

Legal Assistance Center

More Info
Sheller, P.C. (866) 735-1102 Ext 475 www.sheller.com
google
Personal Injury Lawyers Serving: Statewide Pennsylvania, Philadelphia, Norristown, Cheltenham, Chester, Drexel Hill, Folsom, Havertown, King of Prussia, Levittown, Radnor, Springfield, Swarthmore, West Chester, Willow Grove
1528 Walnut Street3rd Floor, Philadelphia, Pennsylvania 19102 [ Show Map ]
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address